Search Results for “E_S4HCON2023 Übungsmaterialien – E_S4HCON2023 Lernführung: SAP Certified Technology Specialist – SAP S/4HANA Conversion and SAP System Upgrade – E_S4HCON2023 Lernguide ♿ Suchen Sie auf ⏩ www.itzert.com ⏪ nach 《 E_S4HCON2023 》 und erhalten Sie den kostenlosen Download mühelos 🕑E_S4HCON2023 Online Prüfung” – Page 42

Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial

87	Magerl, M., Pisarevskaja, D., Scheufele, R., Zuberbier, T., and Maurer, M.+: Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: A prospective trial. Allergy 2010: 65; 78-83. IF: 6.29

364	Kulthanan, K., Chularojanamontri, L., Rujitharanawong, C., Weerasubpong, P., Maurer, M.+, and Weller, K.: Angioedema quality of life questionnaire (AE-QoL) – interpretability and sensitivity to change. Health. Qual. Life Outcomes 2019: 17; 160. IF: 2.34

o.364

27.	Zuberbier, T. and Maurer, M.: EAACI-GA²LEN-EDF-WAO – Guideline on urticaria. In: Akdis, C. A. and Agache, I., editors: Global atlas of allergy. EAACI, 2014

Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence

129.

Maurer, M., Metz, M., Brehler, R., Hillen, U., Jakob, T., Mahler, V., Pföhler, C., Staubach, P., Treudler, R., Wedi, B., and Magerl, M.: Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J. Allergy Clin. Immunol. 2018: 141; 638-649. IF: 14.11

r.129

Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey

359

Bygum, A.+, Caballero, T., Grumach, A. S., Longhurst, H. J., Bouillet, L., Aberer, W., Zanichelli, A., Botha, J., Andresen, I., Maurer, M. for the IOS study group: Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the icatibant outcome survey. Clin. Transl. Allergy 2019: 9; 37. IF: 5.13

o.359

Urticaria: Collegium Internationale Allergologicum (CIA) update 2020

158.

Maurer, M.⁺, Eyerich, K., Eyerich, S., Ferrer, M., Gutermuth, J., Hartmann, K., Jakob, T., Kapp, A., Kolkhir, P., Larenas-Linnemann, D., Park, H.-S., Pejler, G., Sanchez-Borges, M., Schäkel, K., Simon, D., Simon, H.-U., Weller, K., Zuberbier, T., and Metz, M.: Urticaria: Collegium Internationale Allergologicum (CIA) update 2020. Int. Arch. Allergy Immunol. 2020: 181; 321-333. IF: 2.75

r.158

381.	Dortas, S. D. Jr.⁺, Oliveira Rodrigues Valle, S., Weller, K., Maurer, M., and Lupi, O.: Validity, reliability and interpretability of the Brazilian UCT. Allergy Asthma Proc. 2020: 41; e61-e66. IF: 2.59

o.381

Adaptation and initial results of the polish version of the GA²LEN chronic urticaria quality of life questionnaire

106

Brzoza, Z.+, Badura-Brzoza, K., Młynek, A., Magerl, M., Baiardini, I., Canonica, G. W., Weller, K., Kocatürk, E., Kalogeromitros, D., Zalewska-Janowska, A., Zuberbier, T., and Maurer, M.: Adaptation and initial results of the polish version of the GA²LEN chronic urticaria quality of life questionnaire (CU-Q2oL). J. Dermatol. Sci. 2011: 62; 36-41. IF: 3.71

109	Eller, K., Wolf, D., Huber, J. M., Metz, M., Mayer, G., McKenzie A. N. J., Maurer, M. Rosenkranz, A. R.+, and Wolf, A. M.: IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune-suppression. J. Immunol. 2011: 186; 83-91. IF: 5.78

385.	Kulthanan, K., Ungprasert, P., Tuchinda, P., Chularojanamontri, L., Charoenpipatsin, N., and Maurer, M.⁺: Delayed pressure urticaria: a systematic review of treatment options. J. Allergy Clin. Immunol. Pract. 2020: 8; 2035-2049. IF: 8.86

o.385